Q-omics provides the consensus-scored TRAJ33 profile across patient tissues and cancer cell-line models. TRAJ33 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, TRAJ33 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, TRAJ33 RNA expression shows 12,560 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight TGCT, BRCA, and LSCC as cancer lineages where TRAJ33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ33 survival associations across molecular data types. TRAJ33 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ33 RNA expression–survival associations across cancer types. High TRAJ33 expression shows unfavorable associations in TGCT, COAD, STAD and LUSC, but favorable associations in SKCM and ESCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify TGCT as the clearest survival context for TRAJ33 RNA expression.
This table summarizes TRAJ33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ33 shows higher tumor expression in BRCA, STAD and LUAD. The BRCA box plot shows higher TRAJ33 RNA expression in tumor versus normal tissue (log2 FC = +0.217, t-test p = .018).
This table shows molecular features associated with TRAJ33 in patient tissues and cancer cell lines. In patient samples, TRAJ33 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
